contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


redeye-optomed-q3-review-solid-growth-with-a-positive-devices-segment-development

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

AEYE Health @linkedin: UCL’s forskning i LRG1-proteinets rolle indikerer, at diabetesrelaterede nethindeforandringer starter meget tidligere end antaget. Dette giver tidlig screening en helt ny værdi. AI-baserede metoder, såsom AEYE-DS med bærbare kameraer, kan i praksis bringe screening ind i primær sundhedspleje og arbejdsmedicin — der hvor størstedelen af risikopatienterne allerede er. Markedet bevæger sig hurtigt, og teknologien begynder tydeligt at styre, hvordan DR-screening vil blive udført i fremtiden. Tidlig opdagelse er ikke længere en ekstra fordel, men et nyt minimum.                   linkedin.com              Scientists pinpoint early trigger behind diabetic retinopathy - Insight |...    🩺 New research is changing how we think about diabetic retinopathy!  Scientists at University College London have identified a protein called LRG1 as the trigger for the earliest stages of diabetic retinopathy - long before symptoms appear. LRG1...

Lumon-tilladelsen har jeg ikke fundet på NMPA’s hjemmeside, dvs. på de kinesiske myndigheders hjemmeside. Hvis der er opnået tilladelse derfra, så kunne Optomed jo have meddelt dette. Tilsyneladende er den sag også for lille til at blive meddelt. Optomed Aurora har tilladelse. https://www.nmpa.gov.cn/datasearch/search-result.html Kompetent udseende hjemmeside der hos kineserne.

lyqbq.com              欧视博免散瞳眼底照相机Optomed Lumo®-朗逸医疗-临时起搏器|眼科设备网站    欧视博（Optomed）Lumo® 免散瞳眼底照相机是一款兼具手持与固定使用模式的多功能成像设备，适用于多种医疗场景的眼底检查需求。                             Det er til kineserne, Lumoa, af en forhandler fra Shanghai. Virksomheden er en lille virksomhed med omkring 50 ansatte, og omsætningen er nok ikke særlig stor. Men det kan selvfølgelig snart ændre sig.

Græsk politi “Hellenic Police” har anskaffet og trænet i at bruge Aurora. Kameraer vil helt sikkert fortsat dukke op hos større virksomheder/organisationer inden for arbejdsmiljø og sundhed. Hos virksomheder der værdsætter og tager sig af medarbejderne og deres sundhed.                   linkedin.com              #midimedical #sbmsistemi #os1000 #icare #ic100 #optomed #aurora...    MidiMedical successfully completed the supply, installation, and training for the new ophthalmic equipment systems at the medical offices of the Hellenic Police.  As part of the infrastructure upgrade, the following systems were installed:  • Sbm...

Nå, hvad betyder det kursus så længere, når vi ifølge det floodmap alle her i Finland allerede er druknet.  Og halvdelen af Sahara er under vand.

I 2011 kom der en børsmeddelelse om oversvømmelsen, men i år er der ikke udsendt nogen meddelelse, så fabrikkerne er sandsynligvis i orden indtil videre. https://investor.fabrinet.com/news-releases/news-release-details/fabrinet-reports-impact-due-tosevere-flooding-thailand Producentens meddelelser findes her: https://investor.fabrinet.com/financial-information/sec-filings

Den værste vandophobning på over tre meter ser ud til at være kommet helt ned til provinsen ved sydspidsen, altså et godt stykke længere nede end hvor produktionsanlæggene er.

Optomed

Redeye provides an update following Optomed’s Q3 2025 report. The report was solid in our view, with a strong development in the devices segment, and the outlook remains positive. Changes have...

<div class="mfn-body"><p>Redeye provides an update following Optomed’s Q3 2025 report. The report was solid in our view, with a strong development in the devices segment, and the outlook remains positive. Changes have been made to our sales and OPEX forecasts in this update; however, the fair value range remains intact.</p><p><a rel="noopener" href="https://www.redeye.se/research/1136922/optomed-q3-review-solid-growth-with-a-positive-devices-segment-development?utm_source=MFN&amp;utm_medium=pmcour">Read more and download the Research Update.</a><br>&nbsp;<br>Follow companies at Redeye to receive the latest equity research within Life Science and Technology.<br>&nbsp;<br>This is a press release from Redeye - Research Powered Investment Banking. <a rel="noopener" href="https://www.redeye.se/">www.redeye.se/</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/9baf4cd9-0580-479b-a55d-8888bdf1ef2d/optomed-q3-review-solid-growth-with-a-positive-devices-segment-development.pdf" class="mfn-generated mfn-primary">Optomed Q3 (Review) - Solid growth with a positive devices segment development</a></p></div>